Back to Ask the Diabetes Team Ask the Diabetes Team

From Arlington, Washington, USA:

How safe is Lantus if you have retinopathy? I have lost one eye to it, and I am having problems with the other eye.


As you know, Lantus (insulin glargine) is a new insulin analog. Its role in therapy is that it is a long-acting insulin which is given only once a day. We have not used this medication a long time. However, manufacturers of new drugs have to perform studies on medications prior to having them approved by the Food and Drug Administration. Lantus was tested in both patients with type 1 and type 2 diabetes. Retinopathy was specifically studied by means of adverse event reporting and a retinopathy score after pictures were taken of the eye. The number of adverse events was similar to patients using NPH insulin as the long-acting insulin. When the scoring system was used, results were similar in type 1 diabetes patients, but there was a small increase in the retinopathy score in patients with type 2 diabetes. This information is disclosed on the package insert for Lantus. The significance of the small increase is not known at this time. Follow-up studies will probably be done to see if this is a consistent finding, or an isolated finding.


Original posting 18 Jun 2001
Posted to Insulin Analogs


  Back to Ask the Diabetes Team Return to the Top of This Page

Last Updated: Tuesday April 06, 2010 15:09:22
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.